## **Bo Dupont**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1949596/publications.pdf

Version: 2024-02-01

		101543	182427
53	6,713	36	51
papers	citations	h-index	g-index
			5200
55	55	55	5208
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood, 2005, 105, 4878-4884.	1.4	437
2	HISTOCOMPATIBILITY DETERMINANTS IN MULTIPLE SCLEROSIS, WITH SPECIAL REFERENCE TO CLINICAL COURSE. Lancet, The, 1973, 302, 1221-1225.	13.7	426
3	The killer cell immunoglobulinâ€ike receptor (KIR) genomic region: geneâ€order, haplotypes and allelic polymorphism. Immunological Reviews, 2002, 190, 40-52.	6.0	406
4	<i>HLA-C</i> i>–Dependent Prevention of Leukemia Relapse by Donor Activating <i>KIR2DS1</i> . New England Journal of Medicine, 2012, 367, 805-816.	27.0	398
5	Killer Ig-Like Receptor Haplotype Analysis by Gene Content: Evidence for Genomic Diversity with a Minimum of Six Basic Framework Haplotypes, Each with Multiple Subsets. Journal of Immunology, 2002, 169, 5118-5129.	0.8	361
6	Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma. Journal of Immunology, 2003, 171, 6891-6899.	0.8	295
7	Nomenclature for factors of the HLA system, 1996. Tissue Antigens, 1997, 49, 297-321.	1.0	262
8	Nomenclature for factors of the HLA system, 1994. Tissue Antigens, 1994, 44, 1-18.	1.0	252
9	The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation: A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biology of Blood and Marrow Transplantation, 2006. 12. 876-884.	2.0	241
10	HLA alleles determine differences in human natural killer cell responsiveness and potency. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3053-3058.	7.1	239
11	KIR Ligands and Prediction of Relapse after Unrelated Donor Hematopoietic Cell Transplantation for Hematologic Malignancy. Biology of Blood and Marrow Transplantation, 2006, 12, 828-836.	2.0	201
12	Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. Journal of Clinical Investigation, 2012, 122, 3260-3270.	8.2	190
13	Nomenclature for factors of the HLA system, 2002. Tissue Antigens, 2002, 60, 407-464.	1.0	179
14	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8862-8867.	7.1	179
15	KIR2DS1-Positive NK Cells Mediate Alloresponse against the C2 HLA-KIR Ligand Group In Vitro. Journal of Immunology, 2007, 179, 854-868.	0.8	178
16	Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients. Journal of Immunology, 2004, 172, 3289-3296.	0.8	176
17	Infusion of haploâ€identical killer immunoglobulinâ€like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. British Journal of Haematology, 2008, 143, 641-653.	2.5	175
18	Reconstitution in Severe Combined Immunodeficiency by Transplantation of Marrow from an Unrelated Donor. New England Journal of Medicine, 1977, 297, 1311-1318.	27.0	170

#	Article	IF	CITATIONS
19	Spatial Organization of Signal Transduction Molecules in the NK Cell Immune Synapses During MHC Class I-Regulated Noncytolytic and Cytolytic Interactions. Journal of Immunology, 2001, 167, 4358-4367.	0.8	161
20	Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood, 2001, 98, 2922-2929.	1.4	138
21	Killer-cell Immunoglobulin-like Receptor (KIR) Nomenclature Report, 2002. Human Immunology, 2003, 64, 648-654.	2.4	135
22	<i>KIR</i> and <i>HLA</i> Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma. Clinical Cancer Research, 2009, 15, 7330-7334.	7.0	117
23	Description of the Reference Panel of B-Lymphoblastoid Cell Lines for Factors of the HLA System: The B-Cell Line Panel Designed for the Tenth International Histocompatibility Workshop. , 1989, , 11-19.		107
24	Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood, 2010, 115, 3162-3165.	1.4	99
25	Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission. Clinical Cancer Research, 2008, 14, 2740-2748.	7.0	98
26	Visualization of signaling pathways and cortical cytoskeleton in cytolytic and noncytolytic natural killer cell immune synapses. Immunological Reviews, 2002, 189, 161-178.	6.0	91
27	Cutting Edge: Differential Segregation of the Src Homology 2-Containing Protein Tyrosine Phosphatase-1 Within the Early NK Cell Immune Synapse Distinguishes Noncytolytic from Cytolytic Interactions. Journal of Immunology, 2002, 168, 3150-3154.	0.8	76
28	Comparison of multiple in vivo and in vitro parameters in untreated patients with Hodgkin's disease. Cancer, 1976, 38, 1807-1815.	4.1	70
29	Quantitation, selection, and functional characterization of Epstein-Barr virus–specific and alloreactive T cells detected by intracellular interferon-γ production and growth of cytotoxic precursors. Blood, 2002, 99, 1730-1740.	1.4	66
30	Polymorphism and domain variability of human killer cell inhibitory receptors. Immunological Reviews, 1997, 155, 183-196.	6.0	61
31	Cell-Extrinsic MHC Class I Molecule Engagement Augments Human NK Cell Education Programmed by Cell-Intrinsic MHC Class I. Immunity, 2016, 45, 280-291.	14.3	58
32	The Wiskott-Aldrich Syndrome Protein Regulates Nuclear Translocation of NFAT2 and NF-κB (RelA) Independently of Its Role in Filamentous Actin Polymerization and Actin Cytoskeletal Rearrangement. Journal of Immunology, 2005, 174, 2602-2611.	0.8	57
33	The Lytic Potential of Human Liver NK Cells Is Restricted by Their Limited Expression of Inhibitory Killer Ig-Like Receptors. Journal of Immunology, 2009, 183, 1789-1796.	0.8	55
34	NK Cell Tolerance of Self-Specific Activating Receptor KIR2DS1 in Individuals with Cognate HLA-C2 Ligand. Journal of Immunology, 2013, 190, 4650-4660.	0.8	55
35	Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Current Opinion in Immunology, 2004, 16, 634-643.	5 <b>.</b> 5	54
36	Genetic interaction among three genomic regions creates distinct contributions to early- and late-onset type 1 diabetes mellitus. Pediatric Diabetes, 2005, 6, 213-220.	2.9	40

#	Article	IF	Citations
37	Ligand Binding to Inhibitory Killer Cell Ig-Like Receptors Induce Colocalization with Src Homology Domain 2-Containing Protein Tyrosine Phosphatase 1 and Interruption of Ongoing Activation Signals. Journal of Immunology, 2004, 173, 1571-1578.	0.8	36
38	Adrenal 21-Hydroxylase Cytochrome P-450 Genes within the MHC Class III Region. Immunological Reviews, 1985, 87, 123-150.	6.0	34
39	A Panel of Artificial APCs Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Dominant and Subdominant Viral Epitopes for Adoptive Therapy. Journal of Immunology, 2009, 183, 2837-2850.	0.8	33
40	Natural killer cell receptors: Regulating innate immune responses to hematologic malignancy. Seminars in Hematology, 2005, 42, 91-103.	3.4	32
41	Mixed Lymphocyte Culture Technique: Standardization of a Testâ€System with 10 <sup>5</sup> Responding and 10 <sup>5</sup> Stimulating Lymphocytes per 1 ml. Tissue Antigens, 1974, 4, 495-506.	1.0	24
42	The Activating KIR2DS2 Gene Influences NK Alloreactivity and NK Repertoire Blood, 2007, 110, 313-313.	1.4	24
43	Immunology of hematopoietic stem cell transplantation: a brief review of its history. Immunological Reviews, 1997, 157, 5-12.	6.0	19
44	Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4+ T Cell Responses with a Conserved T Cell Receptor Repertoire. Clinical Cancer Research, 2009, 15, 4467-4474.	7.0	19
45	Nomenclature for factors of the HLA system, 2000. International Journal of Immunogenetics, 2001, 28, 377-424.	1.2	18
46	HLA Class I–Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine. Clinical Cancer Research, 2009, 15, 299-306.	7.0	18
47	Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 951-958.	3.0	18
48	Introduction: current concepts in immunity to human cancer and therapeutic antitumor vaccines. Immunological Reviews, 2002, 188, 5-8.	6.0	12
49	Donor Activating KIR2DS1 in Leukemia. New England Journal of Medicine, 2014, 371, 2042-2042.	27.0	12
50	The Effect of Killer Immunoglobulin-Like Receptor (KIR) Ligand Incompatibility on Outcome of Unrelated Donor Bone Marrow Transplantation (UDT) Blood, 2004, 104, 434-434.	1.4	7
51	Visualization of cognate interactions in immune responses. Immunological Reviews, 2002, 189, 5-7.	6.0	0
52	The yin-yang in immunity. Blood, 2004, 104, 3002-3003.	1.4	0
53	The Activating KIR Genes 2DS1 and 2DS2 Regulate NK Alloreactivity In Vitro Blood, 2006, 108, 927-927.	1.4	0